Davunetide Peptide: NAP, AL-108 and the Failed Tau Program

Davunetide is an investigational peptide best known by its research name NAP and its development codes AL-108 (intranasal) and AL-208 (intravenous), with a newer program labeled CP201. It is an eight-amino-acid fragment, sequence NAPVSIPQ, derived from a larger protein called activity-dependent neuroprotective protein, or ADNP. In laboratory models it stabilizes microtubules and reduces abnormal tau, which made it a high-profile candidate for tau-related brain diseases.

The reason davunetide matters as a case study is not a success story. It is a cautionary one. After encouraging preclinical work and early-phase signals, a large, well-designed phase 2/3 trial in progressive supranuclear palsy (PSP) showed no benefit over placebo. That outcome is central to any honest discussion of this peptide.

This guide is educational and not medical advice. Davunetide is not an approved medicine. It is not a wellness supplement, and there is no established human dosing for self-directed use. Nothing here should be read as a protocol.

For broader context on how peptide drugs are evaluated, see what peptides are and the peptide half-life guide.

Davunetide At A Glance

How Davunetide Is Thought To Work

Neurons depend on microtubules, the internal "rails" that move cargo along axons. Microtubule stability is regulated in part by the tau protein. In tauopathies such as Alzheimer's disease and PSP, tau becomes abnormally phosphorylated, detaches and aggregates, and microtubule-based transport suffers.

Davunetide (NAP) is the active core of ADNP, a protein essential for brain development. Preclinical research indicates the peptide interacts with microtubule end-binding proteins EB1 and EB3 through its SIP motif, promoting microtubule assembly and supporting the tau-microtubule interaction. Reported downstream effects in cell and animal models include reduced tau hyperphosphorylation, protection of axonal transport, anti-inflammatory and antioxidant activity, and inhibition of protein aggregation. More recent work describes cell-nucleus penetration as part of a pleiotropic mechanism.

An important nuance emerged after the clinical failure: laboratory studies reported that NAP preferentially interacts with 3-repeat (3R) tau rather than 4-repeat (4R) tau. PSP is fundamentally a 4R tauopathy. If that isoform preference holds, it offers a mechanistic reason why a microtubule-stabilizing peptide might do little in a 4R disease, regardless of how clean its biology looks on paper.

This is a recurring theme for cognitive peptides. Mechanistic elegance in a dish does not guarantee a clinical effect. The same caution applies when reading claims about semax, selank, or cerebrolysin.

What The Human Evidence Actually Shows

Davunetide reached human testing in several indications. The results range from modest early signals to a clear pivotal failure.

The PSP trial is the decisive piece of evidence. Conducted across roughly 48 centers in multiple countries and published by Adam Boxer and colleagues in Lancet Neurology in 2014, it was a rigorous, placebo-controlled study with co-primary endpoints. Davunetide simply did not separate from placebo. Notably, the trial did not perform pharmacokinetic measurements of the drug, so it could not confirm central nervous system exposure or target engagement, which leaves some ambiguity about whether the molecule, the dose, the route, or the disease match was the problem.

A later reanalysis explored possible sex differences, but a subgroup signal in a negative trial is hypothesis-generating, not proof of efficacy. The honest summary is that davunetide has not demonstrated clinical benefit in an adequately powered trial for any indication.

Current Status: From PSP To ADNP Syndrome

Allon Therapeutics developed davunetide and obtained FDA Fast Track designation and a Special Protocol Assessment for the PSP program. After the trial failed, the company's assets were acquired (by Paladin Laboratories). Development did not end entirely. The molecule has been repositioned under the name CP201 as a candidate for ADNP syndrome, a rare neurodevelopmental disorder caused by mutations in the ADNP gene, the very protein NAP is derived from.

The rationale is intuitive: if ADNP function is deficient, supplying its active microtubule-interacting fragment might partially compensate. Preclinical and mechanistic papers describe CP201 resolving aspects of ADNP deficiency, and the peptide has a relatively clean toxicology and tolerability record from its adult trials. But as of this writing, that ADNP-syndrome use remains investigational and has not been validated by a completed pivotal efficacy trial. Tolerability data are not the same as proof that it works.

Safety And Tolerability

Across its trials, davunetide was generally well tolerated, which is part of why it advanced so far. The safety picture below reflects its investigational status: the absence of dramatic toxicity signals is not the same as an established safety profile for ongoing or self-directed use, and pharmacokinetic gaps mean exposure was not always confirmed.

Because davunetide is not a marketed drug, there is no prescribing label defining contraindications, interactions, or monitoring. That alone should make anyone cautious about claims that it is a ready-to-use nootropic.

How To Evaluate A Davunetide Claim

Davunetide is a useful test case for spotting overstated peptide marketing. Ask five questions.

First, is the source citing the actual PSP trial outcome, or only the preclinical microtubule story? Leaving out a 313-patient negative trial is a major omission.

Second, does the claim distinguish "well tolerated" from "effective"? Davunetide was both safe-seeming and ineffective in PSP. Those are separate findings.

Third, does it acknowledge the 3R-versus-4R tau nuance, or does it imply davunetide broadly "fixes tau"? The isoform detail matters.

Fourth, is the dose presented as a recommendation? Trial doses such as 30 mg intranasally twice daily were research conditions, not validated protocols. They are not endorsements of any regimen.

Fifth, is the molecule being marketed for general cognition when its most active current program is a rare genetic syndrome under investigation? That is a common bait-and-switch pattern with cognitive peptides like dihexa.

If a vendor or article cannot pass these checks, treat its davunetide claims with skepticism. And because it is an unapproved research compound, general handling guidance such as how to inject peptides safely does not turn it into an appropriate self-experiment.

Bottom Line

Davunetide (NAP, AL-108, AL-208, CP201) is a scientifically interesting ADNP-derived octapeptide with a genuine, well-characterized microtubule and tau mechanism in the laboratory. That mechanism earned it FDA Fast Track status and a major clinical program.

But the headline fact is the failure. The pivotal phase 2/3 trial in progressive supranuclear palsy showed no benefit over placebo, and no other trial has established clinical efficacy. The peptide is now studied mainly as CP201 for the rare ADNP syndrome, where it remains investigational. Davunetide is not an approved drug, has no validated human dose, and should not be treated as a proven cognitive enhancer. It is a reminder that strong preclinical biology and good tolerability are not the same as a treatment that works.

References

1. Boxer AL, et al. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial (Lancet Neurology, 2014).

2. Gozes I, et al. NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP).

3. Gozes I, et al. Microtubule-stabilizing peptides and small molecules protecting axonal transport and brain function: focus on davunetide (NAP).

4. Magen I, Gozes I. Davunetide: peptide therapeutic in neurological disorders.

5. Quraishe S, et al. NAP (davunetide) preferential interaction with dynamic 3-repeat tau explains differential protection in selected tauopathies (PLOS ONE).

6. Javitt DC, et al. Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia.

7. Morimoto BH, et al. AL-108 and AL-208, formulations of the neuroprotective NAP fragment of activity-dependent neuroprotective protein, for cognitive disorders.

8. Gozes I, et al. The ADNP syndrome and CP201 (NAP): potential and hope (Frontiers in Neurology, 2020).

9. Gozes I, et al. NAP (davunetide): the neuroprotective ADNP drug candidate penetrates cell nuclei explaining pleiotropic mechanisms (Cells, 2023).

10. Alzforum. Davunetide therapeutics overview.